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Abstract  
P. aeruginosa, an increasingly prevalent opportunistic human pathogen, is the most common gram-negative 
bacterium responsible for the nosocomial and community acquired infections. The excessive use of antibiotics 
has not only led to treat the infections but also the emergence of antibiotic resistance. Multidrug resistant P. 
aeruginosa development is currently one of the greatest challenges. Total 100 clinical isolates of P. aeruginosa 
from inpatient and outpatient were studied. Uropathogenic P. aeruginosa infections were higher in females than 
males, ratio was found more among young and elderly debilitated patients. 99% of the clinical isolates were 
resistant to six commonly used antibiotics with the most resistant pattern being Ampicillin (100%), Amoxycillin 
(99%), Co-trimoxazole (99%), Tetracycline (99%), Cefazoline (99%) and Cefuroxime (100%). The invitro 
sensitivity pattern of 100 isolates of P. aeruginosa showed Imipenem (97%), Amikacin (79%), Tobramycin 
(70%), Ceftazidime (62%), Ciprofloxacin (73%), Cefoperazone (60%), Piperacillin (65%), Gentamycin (34%) 
and Cefotaxime (14%) sensitivity.  
------------------------------------------------------------------------ 
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ESBLs producing strains (33%) were also less in number but were much more resistant to β-lactam and other 
antibiotics. Docking of both effective drugs against bacteria (Amikacin and Imipenem) with least resistance 
21% and 3%, respectively, analyzed how these drugs interact with envelope protein to stop its growth. 
Keywords: P. Aeruginosa; Antibiotics; Antibiotic Resistance; Nosocomial Infections; Docking 
1. Introduction 
P. aeruginosa is a versatile bacterium of the class Schizomycetes, order Eubacteriales, family 
Pseudomonadaceae, and genus Pseudomonas [1]. P. aeruginosa is nearly ubiquitous in nature and is quite 
innocuous in most environments. It can be frequently isolated from soil, water [2] and occasionally from normal 
human skin [3]. It can inhabit the nasopharynx and lower digestive tract up to 6%.  Normally human faecal 
carriage of P. aeruginosa is low, around 3% [4]. However, carriage increases with the length of stay in hospital, 
reaching 30%-50% after 3 weeks and thus can present a distinct risk of endogenous infection [5]. P. aeruginosa, 
an increasingly prevalent opportunistic human pathogen, is the most common gram-negative bacterium found in 
nosocomial and community acquired infections. It can infect almost any external site or organ, and therefore, 
can be isolated from various body fluids such as sputum, urine, wounds, eye or ear swabs and from blood [6]. 
P. aeruginosa is the only gram-negative bacillus capable of producing two types of water soluble pigments, 
pyocyanin, a bluish green distinctive non-fluorescent pigment and pyoverdin, a fluorescent greenish-yellow 
pigment [7]. Pyoverdin is produced abundantly in media of low-iron content, and could function in iron 
metabolism in the bacterium, whereas, Pyocyanin (from "pyocyaneus") refers to "blue pus" which is a 
characteristic feature of suppurative infections caused by P. aeruginosa [8]. Aside from pyoverdin and 
pyocyanin, other pigments may also be produced by some strains of P. aeruginosa, including pyorubrin (red), 
and pyomelanin (brown) pigment that’s why also called as Pseudomonas polycolor [9]. 
P. aeruginosa infections are multifactorial and complex to initiate [10].  It usually requires a substantial break in 
first-line defenses. Such a break can result from breach or bypass of normal cutaneous or mucosal barriers (e.g., 
trauma, surgery, serious burns, or indwelling devices). P. aeruginosa infections begin with bacterial attachment 
and superficial colonization of cutaneous or mucosal surfaces. Most P. aeruginosa infections are both invasive 
and toxinogenic. Under favourable nutrient conditions, the mucoid strains of P. aeruginosa produce an 
extracellular hyperviscous exopolymer glycocalyx (Co-polymer of O-acetylated β-1, 4 linked D-Mannuronic 
acid and L-Guluronic acid) in copious amounts that effectively protects bacterial cells from opsonization by 
antibodies, complement deposition, and phagocyte engulfment by providing a barrier against antimicrobial 
agents and the immune system, thereby increasing its virulence and antibiotic resistance [11, 12]. P. aeruginosa 
also releases two extracellular proteases; elastase and alkaline protease [13]. 
P. aeruginosa produces three other soluble proteins: a cytotoxin and two hemolysins. The cytotoxin is a pore-
forming protein. It was originally named leukocidin because of its effect on neutrophils, but it appears to be 
cytotoxic for most eukaryotic cells. Of the two hemolysins, one is a phospholipase and the other is a lecithinase. 
They appear to act synergistically to break down lipids and lecithin [14]. 
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P. aeruginosa produces two extracellular protein toxins, Exoenzyme S and Exotoxin A. Exoenzyme S is an 
exotoxin produced by bacteria growing in burned tissue having ADP-ribosylating activity for a variety of 
eukaryotic proteins and may act to impair the function of phagocytic cells in the bloodstream and internal organs 
to prepare for invasion by P. aerugionsa [15, 16].  Exotoxin A has exactly the same mechanism of action as the 
diphtheria toxin; it causes the ADP ribosylation of eukaryotic elongation factor 2 leading to inhibition of protein 
biosynthesis and cell death. Exotoxin A is responsible for both local and systemic diseases [17, 18]. 
Antibiotics are chemotherapeutic agents that are secondary metabolites of microorganisms. The word antibiotic 
is derived from Greek word that means “against life”. Antibiotics that effectively inhibit bacterial cell wall 
synthesis include the ß-lactams, penicillins, cephalosporins, monobactams and carbapenems. Many drugs 
interfere with protein biosynthesis. These include 50S ribosome inhibitors such as clindamycin, 
chloramphenicol, and the macrolides. The 30S ribosome inhibitors include the tetracyclines and 
aminoglycosides. Within the last two decades, DNA directed RNA polymerase inhibitors such as rifampin for 
Mycobacterium tuberculosis and rifabutin for Mycobacterium avium have also become available. There are a 
large number of DNA gyrase inhibitors such as ciprofloxacin and ofloxacin. The brilliant work of George 
Hitching and Gertrude Elliot showed that a combination of trimethoprim with a sulfonamide (TMP/SMX) 
would synergistically inhibit bacterial folic acid metabolism [19]. 
Unfortunately, as fast as new antibiotics have appeared and they greatly reduced the effects of infectious 
diseases, microorganisms have very cleverly figured out ways to escape their effects. P. aeruginosa may 
develop several mechanisms of resistance against a variety of antibiotics. The major mechanism of resistance to 
β-lactam antibiotics is beta-lactamase production. More than 340 β-lactamase enzymes have been detected to 
date.  
These drug inhibitory agents include the emerging class A SHV and TEM-derived extended-spectrum β 
lactamases (ESBLs), inhibitor resistant enzymes, non-TEM, non-SHV class A ESBLs, and carbenpenemases, 
class B metallo-β-lactamases and some of their novel inhibitor, plasmid and chromosomally encoded class C 
enzyme, and finally, the OXA-type oxacillinases ESBLs, and carbapenemases of class D [20] ESBL producing 
organism pose unique challenges to clinical microbiologists, clinicians, infection control professionals and 
scientist engaged in finding new antimicrobial agents. ESBLs are enzymes capable of hydrolyzing third and 
fourth generation cephalosporins such as ceftazidime, ceftoxime and cefepime as well as aztreonam. Currently, 
carbapenems are regarded as the drug of choice for treatment of infections caused by ESBL-producing 
organisms [21]. 
1.1 Study Objectives 
To determine magnitude, frequency (prevalence) and current trends of antibiotic resistance development among 
clinically significant P. aeruginosa strains causing various nosocomial and community acquired infections 
against various commonly used antibiotics. 
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2. Material and Methods 
2.1 Sample Collection and Identification 
A total of 100 P. aeruginosa isolates were isolated from Pathology Laboratory, District Headquarters Hospital, 
Rawalpindi, Pakistan and identified on the basis of colony morphology according to Berges Manual of 
Determinative Bacteriology, 8th edition.    
Samples of pus, urine, blood, different body fluids, and throat, sputum and ear swabs, both from outdoor 
patients as well as indoor patients from different wards of the hospital were aseptically collected. 
2.2  Processing Of Samples 
Samples were processed as follow: 
2.2.1 Pus Samples 
The appearance of Pus samples was noted and were directly inoculated on Blood agar (CM55 and SR50-
OXOID) and MacConkey agar (CM7-OXIOD) and incubated for 24-48 hrs at 370 C aerobically. 
2.2.2 Urine Samples 
The appearance (colour, whether clear or cloudy) of freshly collected urine was noted. About 10ml of freshly 
received well mixed  urine samples were  centrifuge at 500-1000g for 5 min.By using a sterile calibrated wire 
loop inoculate a urine on a CLED media (Cystine- Lactose –Electrolyte Deficient (CM 301-OXOID). The plates 
were incubated for 24 to 48 hours at 370 C aerobically. The bacterial growth was Sub-cultured on Blood agar 
(CM55 and SR50-OXOID) and MacConkey agar (CM7-OXIOD) and incubated for 24-48 hrs at 370 C 
aerobically. 
2.2.3 Sputum Sample 
Appearance of specimen (purulent, mucopurulent, mucoid, and salivary) was noted. Wash the sputum specimen 
in about 5ml of sterile physiological saline. Then it was streaked on Blood agar (CM55 and SR50-OXOID) and 
MacConkey agar (CM7-OXIOD) and incubated for 24-48 hours at 370 C aerobically. 
2.2.4 Blood Sample 
Freshly drawn 3-5mL blood was immediately transferred to 50mL of brain heart infusion (BHI) broth (CM225-
OXOID), and incubated at 37o C for 24 hours. In case of  no growth, incubation period was extended for another 
24 hours and inspected daily for visible sign of growth. Growth was sub cultured on Blood agar (CM55 and 
SR50-OXOID) and McConkey’s agar (CM7-OXIOD) plates, and incubated at 37o C for 24 hours. For both with 
no growth even after 48 hours the plates were further incubated up to 10 days, the samples were considered as 
negative only if there was no turbidity or growth on tenth day.   
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2.2.5 Ear swabs  
Ear swabs samples were directly swabbed on Blood agar (CM55 and SR50-OXOID) and MacConkey agar 
(CM7-OXIOD) and incubated for 24-28 hours at 370 C aerobically. 
2.2.6 Maintenance of Bacterial Isolates 
For short term storage, the bacterial isolates were cultured on Tryptic Soy agar slants and petriplates and 
maintained at 40 C and sub cultured monthly for routine use. Whereas, for long term storage mid-exponential 
phase isolates were taken in tryptic Soy a broth with 20% glycerol in screw capped tubes and kept at -700 C. 
2.3 Identification and Characterization of Bacterial Strains 
2.3.1 Morphological Identification 
Pure cultures were obtained and colony size, shape, color, diameter and growth characteristics (abundant, thin, 
pigment production) were noted. Isolated colonies were initially gram stained by preparing smear from well 
isolated colonies. Stained smear was examined under microscope to view microscopic characteristics. By using 
Bergey’s Manual of determinative Bacteriology (8th Edition) the isolates were further biochemically 
characterized and identified. 
2.3.2 Biochemical Identification 
The primary identification of unknown bacterial isolates were made based on colonial appearance, 
pigmentation, oxidation-fermentation test, oxidase test, indole test, citrate utilization test, catalase test, 
hemolysis, ability to grow on cetrimide agar, motility test, ability to grow at 50C to 420C and other biochemical 
tests. 
2.3.3 Differentiation of mucoid and non-mucoid strains 
Using  sterile  technique, a  heavy  smear  of  bacterial  isolate  on glass   slide was  prepared , air died , flooded  
with  1%  crystal  violet solution , waited  for  5  to 7 minutes , the  smear  was  washed  with  20% copper  
sulphate  solution , gently  blot  dried  and  was   examined  under  microscope  to  note  the  presence  or  
absence  of  capsule(alginate). Precipitation of alginate was used for confirmation of capsule staining. For each 
isolate, a 48-hour culture was prepared in 100 mL nutrient broth (shaking at 34 – 35°C) and alginate was 
precipitated by the addition of 50 mL cold ethanol. This mixture was kept at –20°C for 30 min until formation of 
the alginate precipitate was complete. 
2.3.4 Cultured Medias, Antibiotic Discs, Control Strain 
Table 1 showed list of chemicals used in this study and their composition. All the antimicrobial Discs used in 
this study, their codes and strength are given in the Table 2. Pseudomonas aeruginosa (ATCC27853) control 
strain was used during study. 
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Table 1: Used Culture Medias and Their Composition 
              Media            Ingredients         Amount(gms/L) 
Nutrient  Broth 
CM-1 
Peptone 
Sodium  Chloride 
Meat extract 
10.0 
5.0 
10.0 
Nutrient Agar 
CM-3 
Peptone 
Sodium  Chloride 
Meat extract 
Agar 
10.0 
5.0 
10.0 
15.0 
Muller  Hinton Agar 
CM-337 
Meat infusion 
Casein  Hydrolysate 
Starch 
Agar 
6.0 
17.5 
1.5 
10.0 
Blood  Agar 
CM-55 
Infusion from beef heart 
Tryptose 
Sodium chloride 
Agar 
Defibrinated  Blood 
500.0 
10.0 
5.0 
15.0 
50.0 
Tryptic  Soy  Agar 
CM-131 
 
 
Phytone 
Tryptose 
Sodium chloride 
Agar 
500.0 
10.0 
5.0 
15.0 
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MacConkey  Agar 
CM-7 
Peptone 
Lactose 
Bile Salt No 3 
Neutral red 
Sodium chloride 
Agar 
20.0 
10.0 
5.0 
0.075 
5.0 
12.0 
Brain Heart Infusion 
CM-225 
Infusion  from  calf  brain 
Infusion   from  beaf  heart 
Peptone 
Dextrose 
Sodium chloride 
Disodium Phosphate 
200.0 
250.0 
10.0 
2.0 
5.0 
2.5 
Pseudomonas Cetrimide  
Agar 
CM-559 
Peptone 
Magnesium  Chloride 
Potassium  Sulphate 
Cetrimide 
Agar 
20.0 
1.4 
10.0 
0.3 
13.6 
 
2.3.5 Antimicrobial Susceptibility Testing 
The disk diffusion method of Bauer et al. (1996) was used for antibiotic susceptibility testing for each bacterial 
isolate on Muller Hinton agar (CM337-OXOID). Medium was prepared and sterilized by autoclaving at 121◦ for 
15 minutes. 25ml of media was poured in 90 mm sterile Petri dishes and incubated at 37ºC overnight to check 
sterility. 
2.3.6 Preparation of 0.5 McFarland Turbidity Standard 
McFarland standard was prepared by adding 99.5ml of 1% sulphuric acid and 0.5ml of 1.175% barium chloride. 
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This McFarland standard provides turbidity comparable to a bacterial suspension containing 1.5 x 108 CFU/ml 
(NCCLS (1993)). 
2.3.7 Inoculum Preparation 
For inoculum preparation 5ml of Tryptic Soya broth (CM129-OXOID) medium was dispensed in screw-capped 
test tubes and autoclaved at 121◦ for 15 minutes. The test tubes were cooled and kept in an incubator for 24 
hours at 35ºC to check sterility.  
Next day one of each identified clinical isolate was inoculated in sterilized test tubes containing media, and 
place in incubator overnight at 35ºC after 24 hours the turbidity of broth cultures were adjusted according to 0.5  
2.3.8 Disc Diffusion (Bauer-Kirby, 1966) Susceptibility test 
A sterile cotton swab was saturated by dipping in to standardized bacterial suspension. Inoculum was spread 
evenly over the entire surface of Mueller –Hinton agar by swabbing back and forth across the agar in three 
directions to give a uniform inoculum to entire surface. The plates were dry and with in 15 minutes discs of 
given potencies (table 2) were applied on inoculated plates. Then plates were placed in incubator at 35ºC for 18 
hour in an inverted position. 
Table 2: Antimicrobial Discs Along With Codes and Potencies Used In Study 
Antimicrobial Agent Antibiotic Group Code Disc Potency (μg) 
Amoxycillin Penicillin AML 25 
Cefazoline Cephalosporin KZ 30 
Co-trimoxazole (Septran) Sulphonamide SXT 25 
Cefuroxime Cephalosporin CXM 30 
Ampicillin Penicillin AMP 10 
Tobramycin Aminoglycoside TOB 10 
Amikacin Aminoglycoside AK 30 
Ceftazidime Cephalosporin CAZ 30 
Cefotaxime Cephalosporin CTX 30 
Piperacillin β-lactamase Inhibitor PRL 100 
Gentamycin Aminoglycoside CN 10 
Tetracycline Tetracycline TE 30 
Ciprofloxacin Quinolones CIP 5 
Cefoperazone Cephalosporin CFP 75 
Imipenem Carbapenem IMP 10 
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2.3.9 Interpretation of Zone Size 
After 18 hours of incubation, plates were examined and zones of inhibition were measured. Using the 
interpretive, interpreted the zone sizes of antimicrobial, and reported the organism sensitive, intermediate, 
resistant according to National Committee for Control Laboratory standards (NCCLS (1993). 
2.4 Computational Analysis 
PatchDock server [22, 23] was used for docking analysis. Total 100 runs were carried out to generate best 
docking complex. The first 10 docked complexes were retrieved and then subjected to FireDock server [24, 25] 
for further analysis (i.e. refinement and ranking of interactions). Docking interactions were analyzed using 
LIGPLOT program [26].  
2.5 Detection of Extended Spectrum Beta Lactamases (Esbls) 
Double disc diffusion method was used to detect the extended spectrum beta lactamases (ESBL). A single, 
separated colony of the test organism was picked and emulsified in 0.9% normal saline in a test tube, the 
turbidity of the test organism was matched with 0.5% McFarland’s Standard. The suspension of test organism 
was spread on the Mueller-Hinton agar surface in a petri plate with the help of cotton swab soaked in suspension 
tube. A disk of co-amoxicilline (20 µg amoxicilline/10µg clavulanic acid) was placed in the center of the agar 
surface. The discs of cephotaxime ceftriaxone, ceftazidime and aztreonam (30 µg) were arranged in such a way 
that the distance between the central disc and surrounding discs was approximately 30 mm. The isolates were 
incubated at 37˚C for 24 hours. After an overnight incubation, the zones around 3rd generation cephalosporins 
discs and aztreonam were observed. If the inhibition zone around one or more cephalosporins discs was 
extended on the side nearest to the co-amoxiclave disc, the organism showing this synergism is an ESBL-
producer. When there was no extension of zones, the test was repeated by reducing the distance between the 
cephalosporins and aztreonam, amoxiclave discs to 20 mm or even less. Zones of inhibition were again 
observed next day .If no extension of 3rd generation of cephalosporins and aztreonam towards co-amoxiclave 
discs was observed, the organisms were considered as non-producer of ESBLs. 
3. Results 
To investigate the rate of prevalence of clinically significant P. aeruginosa strains and their susceptibilities 
against various commonly used antibiotics, a total of 200 samples were selected from the specimens received at 
Pathology Laboratory. Among total, 86 were isolated from males, 92 from females and 22 were isolated from 
environmental sources.  
A series of biochemical tests were conducted for identification and Characterization of   P. aeuroginosa as 
outlined in the Bergey’s Manual of Determinative Bacteriology (9th Edition). Culture sensitivity testing of these 
samples was conducted against 16 most commonly used antibiotics for Pseudomonal infections by means of 
Disc diffusion method [27]. Table 4 indicates the susceptibilities of the 200 isolates. Later on ESBL production 
and glycocalyx (alignate) formation was also studied in order to understand the virulence of these strains.  
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Our collected samples comprised of pus, urine, blood, sputum, ear swabs, and also from environmental sources 
(Table 3). 
 Table 3: Isolation Sources of P. Aeruginosa 
 
 
 
 
 
 
Table 4: Sensitivity Pattern of P. Aeruginosa 
                  Antibiotics         % sensitive 
Ampicillin 0% 
Amoxycillin 1% 
Septran 1% 
Tetracycline 1% 
Cefazoline 1% 
Cefuroxime 0% 
Ceftazidime 62% 
Cefotaxime 14% 
Tobramycin 70% 
Amikacin 79% 
Gentamicin 34% 
Ciprofloxacin 73% 
Piperacillin 65% 
Imipenem 97% 
Cefoperazone 60% 
Ciprofloxacine 39% 
P. aeruginosa was found to be the most prevalent organism throughout the sampling period.  Although, it is an 
opportunistic pathogen, responsible for, nosocomial infection throughout the year but the present data showed 
that most of its occurrence was observed from July-September, covering the months of summer.  
Specimen     P. aeruginosa 
Pus            88 
Sputum            10 
Urine            64 
Blood             18 
Ear  Swab             8 
Environmental             12 
TOTAL           200 
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In case of gender-wise prevalence P. aeruginosa was more prevalent in females (50%) as compared to male 
(46%) patients (Figure 1). It was observed that indoor patients (84%) were more infected with P. aeruginosa 
infection as compared to outdoor patients (15%). 
 
Figure 1: Gender wise Prevalence of ESBL producers among P. aeruginosa 
Out of collected 100 samples of P. aerugionsa, 41 were isolated from pus, 32 from urine, 3 from ear swabs, 4 
from blood, 3 from catheter tip, 5 from sputum and 8 from environmental sources (Table 3). Among clinical 
isolates P. aeruginosa was more prevalent in pus (44%) followed by urine (34%), sputum (5%), blood (4%), 
catheter tips (3%) and ear swabs (3%). 
Among 41 isolates of pus, 23 (57%) were from males and 18 (43%) were from females. Among 32 isolates of 
urine 18 (56%) were from females and 14 (44%) from males. Out of 5 isolates from sputum, 2 (40%) were from 
males and 3 (40%) were from females. 
In case of pus prevalence of P. aeruginosa was more in males (57%) as compared to females (43%). In case of 
urine the prevalence was higher in females (56%) as compare to males (44%). Susceptibility of these clinically 
significant isolates of P. aerugionsa was determined by disc diffusion method against 15 antibiotics. Table. 4 
and Figure 2 indicates the susceptibilities of the 100 isolates. 
Among Penicillin group (β–lactam antibiotics), for Ampicillin (semisynthetic penicillin, β-lactam) none of 
isolates were found sensitive and no isolate show intermediate behavior while rest of the isolates showed highly 
resistant behavior (100%). For Amoxycillin (synthetic penicillin) only 1% isolates showed sensitivity, all of 
them were resistant. Rate of resistance was 99% in this case. 
For Piperacillin (ß-lactamases inhibitor), 65% isolates were sensitive, 3% were intermediate and 32% of isolates 
showed resistance. Three aminoglycosides, i.e. Tobramycin, Amikacin, and Gentamycin were tested against P. 
aeruginosa. Out of these three aminoglycosides,  amikacin showed 79% susceptibility and only 21% resistant 
behavior was exhibited by the P. aeruginosa isolates whereas, Gentamycin showed highest resistance i.e. 66%, 
no organism exhibited intermediate behavior and only 34% isolates showed sensitivity to this drug.  
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For Tobramycin, 70 % organisms showed sensitivity and 30% were resistant. 
Figure 2: Antimicrobial susceptibility pattern in P. aeruginosa 
Among the quinolones and floroquinolones, Ciprofloxacin was used. Results showed that 73% organisms were 
sensitive, 1% were intermediately sensitive and 26% organisms were resistant to it. 
Co-trimoxazole (Septran) was also studied to note the susceptibility pattern of P. aerugionsa against 
Sulphonamides. Only 1% of the isolates showed susceptibility to this combination (Septran) and remaining were 
totally resistant to this antibiotic so resistance was 99%. Among first generation Cephalosporins, Cefazoline 
showed 99% resistance against all the 100 isolates of P. aeruginosa. Cefuroxine, the 2nd generation 
Cephalosporin also showed 100% resistance for all 100 isolates of P. aeruginosa. 
Among 3rd generation Cephalosporins, Ceftazidime and Cefotaxime were used to determine the susceptibility 
pattern. For Ceftazidime, 62% were sensitive and no isolate was intermediate and 38% showed resistance. For 
Cefotaxime, 14% of the total isolates were sensitive, 5% were intermediate and 81% organisms were found to 
resistant to this drug. Tetracycline, although it has lost its efficacy against MDR P. aerugionsa isolates, but it 
was also used to determine resistance of P. aerugionsa against conventionally used old medicines. For 
Tetracycline1% of the isolates were sensitive and 99% organisms were found to be resistant to this drug. 
Cefoperazone (Extended- spectrum cephalosporin) inhibited 60% of the isolates so 60% isolates were sensitive 
to it. A total of 3% isolates showed intermediate behavior, while, 37% isolates were resistant to it. Imipenem 
(Carbapenems) was found to be the most effective antibiotic among all the antibiotics used in this study. The 
percentage of sensitive organisms was 97%, whereas, only 3% were resistant to Imipenem. 
Overall isolates exhibited 100% resistance to Cefuroxime and Ampicillin,, 99% resistance to Tetracycline, 
Cefazoline, Co-trimoxazole and Amoxycillin 30% resistance to Tobramycin, 21% to Amikacin, 66% to 
Gentamycin, 38% to Ceftazidime, 81% to Cefotaxime, 32% to Piperacillin, 26% to Ciprofloxacin, 37% to 
Cefoperazone and 3% to Imipenem (Table 4). 
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No intermediate resistant strains were found in case of Ceftazidime. No isolate was found sensitive to 
Cefuroxime. Whereas, Imipenem showed highest number of sensitive organisms (97%) followed by Amikacin 
(79%) and Ciprofloxacin (73%). Multidrug resistant organisms were found among isolates studied. Few isolates 
showed complete inhibition to all the antimicrobial agents tested for resistance. 
ESBL producing P. aeruginosa isolates are a major cause of nosocomial infections. The present study was 
conducted to determine the prevalence, resistance and phenotypic transfer of ESBLs among P. aeruginosa 
isolates. The detection of ESBL was performed by Double disc diffusion method. Out of 100 isolates, 33 (33%) 
were found to be ESBL producers (Figure 3). 
 
Figure 3: Prevalence of ESBL Producers among P. aeruginosa 
Out of total 41 pus isolates, 14 (34%) were found to be ESBLs producer, 11 (34%) from urine samples out of 
32, 2 (66%) from catheter tip out of 3, 3 (60%) from sputum out of 5, 2 (50%) from blood out of 4 and 4 (50%) 
from Environmental sources out of 8. No ESBL producing strain was found in ear swab and fluid sample. Now-
a-days the newer β-lactams including the third generation cephalosporins in combination with aminoglycosides 
are frequently used in clinical practice for treatment of nosocomial infections caused by MDR gram negative 
bacteria (e.g. P. aerugionsa). But data on bacterial resistance of clinical isolates from hospital showed that the 
resistance of P. aerugionsa to these newer β- lactams is also increasing. 
Protein H1 is envelope protein of Pseudomonas aeruginosa. It protect LPS (Lipopolysaccharide) binding sites 
from highly cationic antibiotics [28]. Hence docking analysis of this envelope protein (NP_249869.1) was done 
with drugs Amikacin and Imipenem. These two drugs were selected because both were effective on bacteria 
with least resistance 21% and 3%, respectively, according to experimental results. These results show that drugs 
work on this microorganism by affecting this envelope protein. For docking studies receptor H1 envelope 
protein three dimensional structure was obtained from RCSB-PDB database. Ligands (Amikacin and Imipenem) 
were obtained from chemspider ligand database. Both ligand molecules have chemspider ID 34635 and 94631, 
respectively. Docking was performed for both ligands with same receptor protein. Structure of H1 protein 
receptor has been shown in Figure 4 (a).  
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Its part b and c shows ligand drugs Amikacin and Imipenem, respectively. Docking complex of receptor with 
ligands amikacin and imipenem are shown in Figure 4 (part d and e). 
 
 
 
 
 
 
 
 
a 
b c 
d e 
 
Figure 4: Docking Results: a) 3D-Structure of H1 Protein, b) Amikacin Ligand, c) Imipenem Ligand, d) 
Docking Results for H1 Receptor with Amikacin Ligand. e) Docking Results for H1 Receptor with Imipenem 
Ligand. Viewer: Viewerlite v5.0. H1 Protein color by secondary type and Schematic display style. Ligand: Ball 
& Stick Display style. 
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Table 5: Receptor (H1) and Ligand (Amikacin and Imipenem) Residues Involved in Interactions 
 
Table contains docking results of receptor/ligand residues involved in the interaction for both dockings (HR 
protein with both ligands). Specific residues or atoms of ligand and receptor are involved in docking interaction. 
These ligand/receptor residues dock with the help of non-covalent interactions, for example hydrogen bonding 
and hydrophobic interactions. Residues/atoms of both receptor and ligand involved in hydrogen bonding and 
hydrophobic interaction are given in Table 5.  
Difference in the interaction sites can be estimated through the amino acids and atoms which are involved in the 
hydrogen bonding and hydrophobic interactions between ligand and binding site of receptor protein. LigPlot 
results for the docking interactions are shown in Figure 5. 
Receptor Residues Involved in Hydrophobic Interactions are shown in black color and represented by brick red 
spoked arcs ( ). Green dotted lines ( ) show hydrogen Bonding. Receptor residues involved in H-
Bonding are shown in Olive Green Color. Ligand Atoms involved in H-Bonding are shown in pink color. 
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Leu71, 
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Gly108,  
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Lys112,  
O1, O2, O3, O4, O5,  O6, 
O7, O8, O9, O10, O11, 
O12, C29, O13, C23, C38, 
C31, O10, N10,  N16,  N17, 
C20, C21, C22, C23, C25, 
C26, C27, C28, C29,  C30, 
C31, C32, C34, C35, C36, 
C37, C38 
Arg72, Leu104, Gln106, 
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O4 Gln52 S1, O2,  O3,  O4, O5,  N6, 
N7, N8,   C9, C10, C11, 
C12, C13, C14, C15, C16, 
C17, C18, C19, C20 
Gln48, Gln49, Phe50, 
Gly53, Arg54, Tyr55, 
Tyr80, Asp81, Ala82, 
Gly95, Gly96, Ala97, 
Leu123 
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a 
b 
Figure 5: LigPlot Results for Docking Interactions; a) H1 with Amikacin, b) H1 with Imipenem. Ligand 
Atoms Involved in Hydrophobic Interactions are shown in blue color and represented by pink spoked arcs 
( ). 
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4. Discussion and Conclusion 
Our results showed a significant increase in the number of P. aeruginosa strains isolated from pus followed by 
urine. Similar pattern of isolation of P. aeruginosa from pus, urine, ear, nose, wound and other infection sites 
was reported by [29]. but in a study conducted by [30]. P. aeruginosa was mostly isolated from urine samples. 
This could be attributed due to differences in geographical location and hygienic measures or due to the fact that 
most patients going for major surgery tend to get catheterised.  
In the present study, uropathogenic P. aeruginosa was found higher in females than males. Ratio was also found 
more among young and elderly debilitated patients. The one reason may be that P. aeruginosa may be a 
common inhabitant of lower intestinal tract and in female the distance between anal and vaginal opening is 
small, thus P. aeruginosa through fecal contamination invade and colonized urinary tracts causing infection  
[31] have suggested that the ascending infection from the lumen of the drainage tube may be the major pathway 
by which bacteria gain access to the urinary bladder  [32] have also documented a higher risk for developing 
bacteriuria in adult female patients, the elderly and critically ill patients with a urinary catheter. Longer stay in 
the hospital increases the colonization of skin and environment of the patient and may be responsible for higher 
incidence of Urinary catheter related infections [33]. 
In the present study, blood, ear swabs, and sputum samples were so less to comment on, this may be due to the 
low number of blood, ear swabs and sputum samples sent from wards and OPDs during the study period. 
However P. aeruginosa is said to be responsible for pneumonia and septicaemia with attributable deaths 
reaching 30% in immunocompromised patients [34, 35, 36].The possibility of aspiration Pseudomonal 
pneumonia cannot be ruled out in post-surgical patients especially if immunocompromised [29]. 
 P. aeruginosa was also isolated from the hands of the nursing staff. This is in agreement with [37] who reported 
that the hands of nurses working in wards with infected patients often carry P. aeruginosa. Similar kind of 
results was reported by [38]. 
 P. aeruginosa is currently one of the most frequent nosocomial pathogen and the infections due to this organism 
are often difficult to treat due to antibiotic resistance [39]. The mechanisms of resistance to antibiotics include 
reduced cell wall permeability, production of chromosomal and plasmid mediated     ß-lactamases, [40] 
aminoglycoside-modifying enzymes [41] and an active multidrug efflux mechanism [42, 43]. 
In the present study, the susceptibility of 100 clinical isolates of P. aeruginosa from pus, blood and 
miscellaneous samples, towards various antimicrobial agents was determined by disc diffusion method. Highest 
resistance (100%) was found against cefuroxime and amoxicillin. The next most resistant antibiotics were 
ampicillin (99%), Septran (99%), Tetracycline (99%) and Cefazoline (99%), Cefotaxime (81%), Gentamycin, 
(66%) Ceftazidime (38%), Cefoperazone (37%), Piperacillin (32%), Tobramycin (30%), Amikacin (21%) and 
Imipenem (3%). Among  most  commonly  used  cephalosporins, Ceftazidime and Cefoperazone  proved  to  be  
most  effective against P. aerugionsa, with resistant  rate of  (38%)  and  (37%) respectively. Among first 
generation cephalosporins, cephradine and cephalexin were tested   against P. aeruginosa isolates.  
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Most of the isolates (88%) in this study were cephradine resistant and 80% were resistant to cephalexin. Earlier 
studies [44, 45] found P. aerugionsa to be resistant   to these agents. 
Among second generation cephalosporins, P. aerugionsa showed 100% resistance against cefuroxime [46].  It 
was previously reported that none of  the  first  or  second generation  cephalosporins  are  active  against  P. 
aeruginosa [47]. 
Third generation cephalosporin group included commonly used  antibiotics  cefotaxime,  Ceftazidime,  
Cefoperazone  and  ceftriaxone,  which  were  tested  against  P. aerugionsa  isolates. Among  third-generation  
cephalosporins,  ceftriaxone  use was found  to be less active,  as  67%  isolates  were  resistant. Other workers 
[47, 48] have obtained variable results with this antibiotic.  
Among  cephalosporins, however, Ceftazidime  and  Cefoperazone  were  found  to  be  most  effective third-
generation cephalosporins  as  only 38%  and  37%  isolates  were  resistant. This finding is consistence with 
other findings [49, 50]. 
Among penicillins maximum resistance was noted for ampicillin (99%) and amoxicillin (100%). Similar kind of 
results had also been reported by [38]. An important striking feature found in this study was increased resistance 
to gentamycin (66%) whereas the strains were sensitive to amikacin and tobramycin. Various workers have also 
reported the increased sensitivity of P. aeruginosa strains to amikacin and resistance to gentamicin [51, 52].  
P. aeruginosa Isolates showed resistance towards various antibiotics such as cephalosporins, tetracycline and 
gentamicin. Majority of the P. aeruginosa strains   from the present  study  was  MDR  especially  the  isolates  
recovered  from  pus. Such multiple resistance patterns have also been documented earlier [53].  
During the study, we observed that the alginate capsules of mucoid strains of P. aeruginosa could not act as a 
barrier against imipenem. This finding is comparable to the results of Slack and Nichol’s studies, in which 
alginate impeded the penetration of all antibiotics except the ß- lactams [54] However, the alginate 
glycocalyx provides a barrier against penetration of cefotaxime, and this antibiotic was clearly inferior to 
imipenem against our P. aeruginosa strains. In addition, this reduced susceptibility may be related to the more 
extensive use of cefotaxime in hospital. On the other hand, additional resistance mechanisms especially 
production of extended-spectrum β-lactamases (ESBLs) and other enzymes may contribute to ceftazidime 
resistance [55]. 
Alginate, an extracellular glycocalyx, probably acts as a barrier against aminoglycosides [56]. The mucoid 
strains of P. aeruginosa were found statistically significantly more resistant to amikacin, gentamicin and 
tobramycin than the non- mucoid strains by [57]. Similar types of results were found in the present study. 
Overall, there was moreresistance to gentamycin, followed by tobramycin and amikacin.The results of this study 
suggest that the capsule may act as a barrier against aminoglycosides [58]. Nevertheless, there is evidence that 
alginate provides an ionic barrier against penetration of aminoglycoside antibiotics [56]. Reference [54] used 
antibiotic diffusion through agar as a criterion for direct measurement of the permeability of the alginate layer to 
antibiotics.  
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They found that, with the exception of β-lactams, alginate did in fact impede the penetration of antibiotics such 
as aminoglycosides. However, [59] observed that the alginate-to-anti-biotic ratio could greatly influence the 
perceived permeability barrier. When this ratio is high, aminoglycosides (but not β-lactams) are retained in the 
alginate layer. However, low alginate-to-antibiotic ratios quickly result in disruption of the gel structure and 
faster penetration of amino-glycosides. [57] suggested that high levels of antibiotic saturate the negative charge 
of alginate and result in a breakdown in the permeability layer. 
The development of antimicrobial resistance is a natural process, which cannot be stopped. Resistance means 
that people cannot be effectively treated, that they are ill for longer period of time and at a greater risk of dying. 
It also means that epidemics are prolonged and thus that there is a greater risk of infection to others. The 
development of resistance is accelerated when antimicrobials are misused (http://www.emro.who.net). 
Despite the use of potent antibiotics still high mortality exist in case of P. aeruginosa infections. Nosocomial 
multidrug resistant P. aeruginosa is an important health care problem worldwide. Antimicrobial  resistance  
prolongs  the  duration  of hospitalization,  thereby  increasing  the  cost  of patient  care. There  are  multiple  
factors,  which  contribute  to  the global  spread  of  resistance. Decreasing  unnecessary  antibiotic  use, 
treating  with narrow  spectrum  agents,  improving  compliance  with  therapy,  decreasing  use  of antibiotic  in 
animal  and  agriculture,  and  improving  infection  control all have  a  role  in confronting  this problem.  In 
addition,  immunization  may  diminish  the impact of resistance  by preventing   infection  and  also the  
carriage  of transmission. 
Amikacin and Imipenem drugs were selected for docking because both were effective on bacteria with least 
resistance 21% and 3%, respectively, according to experimental results. These results show that drugs work on 
this microorganism by affecting this envelope protein. Docking results analyzed how these drugs interact with 
envelope protein to stop its growth. 
5. Recommendations 
Molecular docking analysis can be performed while working with various microorganisms and some potential 
drugs can be suggested on basis of resistance. This will lead to more detailed docking analysis and interaction of 
various drugs. 
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